Tarsus to Participate in Upcoming Investor Conferences
Tarsus Pharmaceuticals (NASDAQ: TARS) has announced its participation in three major upcoming investor conferences in June 2025. The company will present at the William Blair 45th Annual Growth Stock Conference on June 3rd at 6:00 AM PT, the Jefferies Global Healthcare Conference on June 4th at 12:45 PM PT, and the Goldman Sachs 46th Annual Global Healthcare Conference on June 9th at 10:20 AM PT. Live webcasts will be available on Tarsus's website, with replays accessible within 48 hours and archived for a limited time.
Tarsus Pharmaceuticals (NASDAQ: TARS) ha annunciato la sua partecipazione a tre importanti conferenze per investitori previste per giugno 2025. La società interverrà al William Blair 45th Annual Growth Stock Conference il 3 giugno alle 6:00 AM PT, al Jefferies Global Healthcare Conference il 4 giugno alle 12:45 PM PT, e al Goldman Sachs 46th Annual Global Healthcare Conference il 9 giugno alle 10:20 AM PT. Le presentazioni saranno trasmesse in diretta sul sito di Tarsus, con repliche disponibili entro 48 ore e archiviate per un periodo limitato.
Tarsus Pharmaceuticals (NASDAQ: TARS) ha anunciado su participación en tres importantes conferencias para inversores que se celebrarán en junio de 2025. La compañía presentará en la William Blair 45th Annual Growth Stock Conference el 3 de junio a las 6:00 AM PT, en la Jefferies Global Healthcare Conference el 4 de junio a las 12:45 PM PT, y en la Goldman Sachs 46th Annual Global Healthcare Conference el 9 de junio a las 10:20 AM PT. Las transmisiones en vivo estarán disponibles en el sitio web de Tarsus, con repeticiones accesibles dentro de las 48 horas y archivadas por tiempo limitado.
Tarsus Pharmaceuticals (NASDAQ: TARS)는 2025년 6월에 열리는 세 개의 주요 투자자 컨퍼런스에 참여한다고 발표했습니다. 회사는 William Blair 45th Annual Growth Stock Conference에 6월 3일 오전 6시(태평양 표준시), Jefferies Global Healthcare Conference에 6월 4일 오후 12시 45분(태평양 표준시), 그리고 Goldman Sachs 46th Annual Global Healthcare Conference에 6월 9일 오전 10시 20분(태평양 표준시)에 발표할 예정입니다. 라이브 웹캐스트는 Tarsus 웹사이트에서 제공되며, 재방송은 48시간 이내에 시청 가능하고 제한된 기간 동안 아카이브됩니다.
Tarsus Pharmaceuticals (NASDAQ: TARS) a annoncé sa participation à trois grandes conférences pour investisseurs prévues en juin 2025. La société présentera lors de la William Blair 45th Annual Growth Stock Conference le 3 juin à 6h00 PT, de la Jefferies Global Healthcare Conference le 4 juin à 12h45 PT, et de la Goldman Sachs 46th Annual Global Healthcare Conference le 9 juin à 10h20 PT. Des webdiffusions en direct seront disponibles sur le site de Tarsus, avec des rediffusions accessibles dans les 48 heures et archivées pour une durée limitée.
Tarsus Pharmaceuticals (NASDAQ: TARS) hat seine Teilnahme an drei wichtigen Investorenkonferenzen im Juni 2025 angekündigt. Das Unternehmen wird auf der William Blair 45th Annual Growth Stock Conference am 3. Juni um 6:00 Uhr PT, der Jefferies Global Healthcare Conference am 4. Juni um 12:45 Uhr PT und der Goldman Sachs 46th Annual Global Healthcare Conference am 9. Juni um 10:20 Uhr PT präsentieren. Live-Webcasts sind auf der Website von Tarsus verfügbar, mit Wiederholungen, die innerhalb von 48 Stunden abrufbar sind und für eine begrenzte Zeit archiviert werden.
- None.
- None.
IRVINE, Calif., May 29, 2025 (GLOBE NEWSWIRE) -- Tarsus Pharmaceuticals, Inc. (NASDAQ: TARS), today announced that management plans to participate in the following upcoming investor conferences:
- William Blair 45th Annual Growth Stock Conference on Tuesday, June 3rd, at 6:00 a.m. PT / 8:00 a.m. CT
- Jefferies Global Healthcare Conference on Wednesday, June 4th, at 12:45 p.m. PT / 3:45 p.m. ET
- Goldman Sachs 46th Annual Global Healthcare Conference on Monday, June 9th, at 10:20 a.m. PT / 1:20 p.m. ET
Live webcasts and additional information can be accessed on the events section of the Tarsus website. Replays will be available on the Tarsus website within 48 hours and will be archived for a limited time.
About Tarsus Pharmaceuticals, Inc.
Tarsus Pharmaceuticals, Inc. applies proven science and new technology to revolutionize treatment for patients, starting with eye care. Tarsus is advancing its pipeline to address several diseases with high unmet need across a range of therapeutic categories, including eye care and infectious disease prevention. XDEMVY® (lotilaner ophthalmic solution)
blepharitis. Tarsus is also developing TP-04 for the potential treatment of Ocular Rosacea, and TP-05 as an oral tablet for the potential prevention of Lyme disease.
Media Contact:
Adrienne Kemp
Sr. Director, Corporate Communications
(949) 922-0801
AKemp@tarsusrx.com
Investor Contact:
David Nakasone
Head of Investor Relations
(949) 620-3223
DNakasone@tarsusrx.com
FAQ
Which investor conferences will Tarsus Pharmaceuticals (TARS) attend in June 2025?
What time is Tarsus Pharmaceuticals' (TARS) presentation at the William Blair conference?
Where can investors watch Tarsus Pharmaceuticals' (TARS) conference presentations?
When is Tarsus Pharmaceuticals (TARS) presenting at the Goldman Sachs Healthcare Conference?
